No Data
Express News | Genprex CMO Reports Clincal Study Updates From Acclaim-1 And Acclaim-3 Phase 1/2 Clinical Trials In Lung Cancer
Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials
Express News | Genprex Shares Are Trading Lower. The Company Announced Updates From Its Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials for Lung Cancer and Ceased Enrollment in Its Acclaim-2 Clinical Trial Due to Patient Recruitment Difficulties
Genprex Stock Slides 14% Following Reqorsa Study Updates
Express News | Genprex Decides To Cease Enrollment In The Acclaim-2 Clinical Trial Due To Difficulties In Recruiting Patients, Citing Competition From Numerous Other Trials.; Limiting The Acclaim-1 Trial To A Single Cohort Due To Resource Prioritization, Reducing...
Express News | Genprex Inc: Expects to Conduct an Interim Analysis in Phase 2a Expansion of Acclaim-1 Study by H1 2025
No Data
